Last Updated on: 07 July, 2024|Author: Getaka | Social:
Fundamental Analysis of Gland Pharma Ltd
About the Company - Gland Pharma Ltd
Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1978PLC002276 and registration number is 002276. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 4400.71 Cr. and Equity Capital is Rs. 16.43 Cr. for the Year ended 31/03/2022.
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
Undervalued: 7.00% compared to the current price 1840
Intrinsic Value: 1,934.31
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.
Undervalued: 5.13% compared to the current price ₹1840
Last 5 Year EPS CAGR: -1.75%
*Investments are subject to market risks
Strength and Weakness of Gland Pharma Ltd Stock
Strength
Weakness
The stock has a high average ROCE of 27.58%, which is a positive sign.
The company has higher reserves (3,476.62 cr) compared to borrowings (54.31 cr), indicating strong financial stability.
The company has shown consistent growth in sales (252.85 cr) and profit (320.54 cr) over the years.
The stock has a high average Working Capital Days of 151.58, which may not be favorable.
The stock has a high average Cash Conversion Cycle of 256.33, which may not be favorable.
FAQ
What is the latest fair value of Gland Pharma Ltd?
The latest fair value of Gland Pharma Ltd is ₹1968.81.
What is the Market Cap of Gland Pharma Ltd?
The Market Cap of Gland Pharma Ltd is 30,310 Cr..
What is the current Stock Price of Gland Pharma Ltd as on 06 July 2024?
The current stock price of Gland Pharma Ltd as on 06 July 2024 is 1,840.
What is the High / Low of Gland Pharma Ltd stocks in FY 2024?
In FY 2024, the High / Low of Gland Pharma Ltd stocks is 2,196/1,056.
Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Gland Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
